TSX-V:NGEN - TSX Venture Exchange - CA64082X2032 - Common Stock - Currency: CAD
TSX-V:NGEN (7/23/2025, 7:00:00 PM)
3.8
+0.2 (+5.56%)
The current stock price of NGEN.CA is 3.8 CAD. In the past month the price increased by 5.56%. In the past year, price increased by 32.4%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
BHC.CA | BAUSCH HEALTH COS INC | 1.75 | 3.34B | ||
CRON.CA | CRONOS GROUP INC | 15.72 | 1.09B | ||
TLRY.CA | TILRAY BRANDS INC | N/A | 1.03B | ||
DHT-UN.CA | DRI HEALTHCARE TRUST | 6.94 | 826.17M | ||
GUD.CA | KNIGHT THERAPEUTICS INC | 55.64 | 609.74M | ||
ACB.CA | AURORA CANNABIS INC | 132.6 | 363.72M | ||
WEED.CA | CANOPY GROWTH CORP | N/A | 334.09M | ||
CPH.CA | CIPHER PHARMACEUTICALS INC | 25.96 | 325.89M | ||
OGI.CA | ORGANIGRAM GLOBAL INC | 35 | 281.15M | ||
HITI.CA | HIGH TIDE INC | N/A | 264.71M | ||
XLY.CA | AUXLY CANNABIS GROUP INC | 15 | 200.29M | ||
TSND.CA | TERRASCEND CORP | N/A | 185.00M |
NervGen Pharma Corp. operates as a clinical stage biotech company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The firm is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The company has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The firm's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.
NERVGEN PHARMA CORP
112-970 Burrard Street, Unit 1290
Vancouver BRITISH COLUMBIA V7X 1J1 CA
CEO: Paul Brennan
Employees: 7
Phone: 17787311711
The current stock price of NGEN.CA is 3.8 CAD. The price increased by 5.56% in the last trading session.
The exchange symbol of NERVGEN PHARMA CORP is NGEN and it is listed on the TSX Venture Exchange exchange.
NGEN.CA stock is listed on the TSX Venture Exchange exchange.
8 analysts have analysed NGEN.CA and the average price target is 9 CAD. This implies a price increase of 136.88% is expected in the next year compared to the current price of 3.8. Check the NERVGEN PHARMA CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NERVGEN PHARMA CORP (NGEN.CA) has a market capitalization of 276.75M CAD. This makes NGEN.CA a Micro Cap stock.
NERVGEN PHARMA CORP (NGEN.CA) currently has 7 employees.
NERVGEN PHARMA CORP (NGEN.CA) has a support level at 3.34 and a resistance level at 3.96. Check the full technical report for a detailed analysis of NGEN.CA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NGEN.CA does not pay a dividend.
NERVGEN PHARMA CORP (NGEN.CA) will report earnings on 2025-08-20.
NERVGEN PHARMA CORP (NGEN.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
ChartMill assigns a technical rating of 6 / 10 to NGEN.CA. When comparing the yearly performance of all stocks, NGEN.CA is one of the better performing stocks in the market, outperforming 79.75% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to NGEN.CA. The financial health of NGEN.CA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months NGEN.CA reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS decreased by -8.65% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -161.68% | ||
ROE | -1843.02% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to NGEN.CA. The Buy consensus is the average rating of analysts ratings from 8 analysts.